Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, Christopher E. Brightling, Guy G. Brusselle, Roland Buhl, Alvaro A. Cruz, Liesbeth Duijts, Jeffrey M. Drazen, J. Mark FitzGerald, Louise J. Fleming, Hiromasa Inoue, Fanny W. Ko, Jerry A. Krishnan, Mark L. Levy, Jiangtao Lin, Kevin Mortimer, Paulo M. Pitrez, Aziz Sheikh, Arzu A. Yorgancioglu, Louis-Philippe Boulet
European Respiratory Journal 2021; DOI: 10.1183/13993003.02730-2021
Helen K. Reddel
1The Woolcock Institute of Medical Research and The University of Sydney, Sydney, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen K. Reddel
  • For correspondence: helen.reddel@sydney.edu.au
Leonard B. Bacharier
2Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, TN, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leonard B. Bacharier
Eric D. Bateman
3Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric D. Bateman
Christopher E. Brightling
4Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher E. Brightling
Guy G. Brusselle
5Ghent University Hospital, Ghent, Belgium and Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy G. Brusselle
Roland Buhl
6Pulmonary Department, Mainz University Hospital, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvaro A. Cruz
7Federal University of Bahia, Salvador, BA, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liesbeth Duijts
8Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Liesbeth Duijts
Jeffrey M. Drazen
9Brigham and Woman's Hospital and Harvard Medical School, Boston, MA, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeffrey M. Drazen
J. Mark FitzGerald
10University of British Columbia, Vancouver, BC, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Mark FitzGerald
Louise J. Fleming
11Imperial College, London, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louise J. Fleming
Hiromasa Inoue
12Kagoshima University, Kagoshima, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiromasa Inoue
Fanny W. Ko
13The Chinese University of Hong Kong, Hong Kong.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fanny W. Ko
Jerry A. Krishnan
14Breathe Chicago Center, University of Illinois Chicago, Chicago, IL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jerry A. Krishnan
Mark L. Levy
15Locum GP, London, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark L. Levy
Jiangtao Lin
16China-Japan Friendship Hospital, Peking University, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiangtao Lin
Kevin Mortimer
17Liverpool School of Tropical Medicine, Liverpool, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Mortimer
Paulo M. Pitrez
18Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paulo M. Pitrez
Aziz Sheikh
19Usher Institute, The University of Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aziz Sheikh
Arzu A. Yorgancioglu
20Celal Bayar University, Department of Pulmonology, Manisa, Turkey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arzu A. Yorgancioglu
Louis-Philippe Boulet
21Quebec Heart and Lung Institute, Universite Laval, Quebec, QC, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louis-Philippe Boulet
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes.

GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as- needed combination ICS-formoterol reduces severe exacerbations by >60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function and inflammatory outcomes as daily ICS plus as-needed SABA.

Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as-needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta2-agonist (LABA) (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11  years, new treatment options are added at Steps 3-4.

Across all age-groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment and review remain essential to optimize asthma outcomes.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Leonard B. Bacharier reports receiving royalties for textbooks from Elsevier; consulting fees from GlaxoSmithKline, Teva, AstraZeneca, Sanofi, Regeneron, Vectura, Circassia, Kinaset, Merck and Boehringer Ingelheim; honoraria for lectures from GlaxoSmithKline, Genentech/Novartis, Teva Honoraria, AstraZeneca, Sanofi/Regeneron and WebMD/Medscape; participation on a Data Safety Monitoring Board or Advisory Board for DBV Technologies, AstraZeneca and Vertex (CF Foundation); leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid for AAAAI Board of Directors (unpaid) and ABAI Board of Directors, in the past 36 months.

Conflict of interest: Eric D. Bateman reports receiving advisory boards, consultant and speaker fees from AstraZeneca, Sanofi Genzyme, Regeneron, Novartis and ALK; speaker fees from Boehringer Ingelheim, Menarini and Orion; and advisory boards and speaker fees from Chiesi, since the initial planning of this work. Eric D. Bateman reports receiving consulting fees from AstraZeneca, Sanofi Genzyme, Regeneron, Novartis and ALK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Menarini, Orion, Novartis, Regeneron, Sanofi Genzyme, Chiesi and ALK; support for attending meetings and/or travel from Novartis (to attend European Respiratory Society Congress 2021); participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, ALK, Sanofi Genzyme, Regeneron, Novartis and Chiesi; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Global Initiative for Asthma (Member of Board and Science Committee, unpaid), in the past 36 months.

Conflict of interest: Christopher E. Brightling reports receiving grants or contracts from GSK, AZ, Novartis, Chiesi, BI, Mologic, 4DPharma, Gossamer, Merck and Roche/Genentech (all paid to Institution); consulting fees from AZ, Novartis, Chiesi, BI, Mologic, TEVA, 4DPharma, Gossamer, Regeneron, Sanofi and Roche/Genentech (all paid to Institution), in the past 36 months.

Conflict of interest: Guy G. Brusselle reports receiving payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi and Teva; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, MSD, Novartis, Sanofi and Teva, in the past 36 months.

Conflict of interest: Roland Buhl reports grants from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche; lecture honoraria from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Novartis, Roche, Sanofi, Teva; participation on advisory board from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Roche, Sanofi, Teva; outside the submitted work; and has acted as a Member of the Scientific Committee of the Global Initiative for Asthma (GINA).

Conflict of interest: Alvaro A. Cruz reports lecture honoraria from Abdi Ibrahim, AstraZeneca, Boehringer Ingelheim, Chiesi, Glennmark, GSK, Mylan, Novartis, Sanofi; travel support from AstraZeneca; Boehringer Ingelheim; Chiesi; outside the submitted work.

Conflict of interest: Liesbeth Duijts reports grants from European Union's Horizon 2020 research and innovation programme (LIFECYCLE, grant agreement No 733206, 2016; EUCAN-Connect grant agreement No 824989; ATHLETE, grant agreement No 874583), outside the submitted work.

Conflict of interest: J. Mark FitzGerald reports grants from Astra Zeneca, GSK, TEVA, SANOFI, CIHR, NIH; consulting fees and lecture honoraria from Astra Zeneca, GSK, TEVA, SANOFI; outside the submitted work.

Conflict of interest: Louise J. Fleming reports consulting fees from GSK, Sanofi, Respiri UK, Astra Zeneca; lecture honoraria from Novartis, Teva; outside the submitted work.

Conflict of interest: Hiromasa Inoue reports grants to institution to Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, MerckSharp&Dohme, Ono; personal consulting fees from Boehringer-Ingelheim; lecture honoraria from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, MerckSharp&Dohme, Novartis, Sanofi; has participated on an advisory board for AstraZeneca, GlaxoSmithKline, Novartis, Sanofi; board leadership with Board of Directors & Chairman of Education Committee in Japanese Respiratory Society, Former Chairman of Education Committee in Japanese Society of Allergology; outside the submitted work.

Conflict of interest: Fanny W. Ko reports support for travel from Novartis, Boehringer Ingelheim and GSK, outside the submitted work.

Conflict of interest: Jerry A. Krishnan reports grants from Regeneron Pharmaceuticals, Sergey Brin Family Foundation, Patient Centered Outcomes Research Institute, COPD Foundation, American Lung Association; consulting fees from GlaxoSmithKline for COVID-19 mAb; board leadership at COPD Foundation, Respiratory Health Association; outside the submitted work.

Conflict of interest: Mark L. Levy reports grants from Consorzio Futuro in Ricerca, Astra Zeneca; royalties from Class Publishing, Taylor & Francis; consulting fees from Respiri, Ltd, TEVA, NSHI Ltd; lecture honoraria from TEVA, Novartis, Chiesi, Orion; payment for expert testimony from HM Coroner Walthamstow, London, HM Coroner, Waltham Forrest, London; travel support from Orion Pharmaceuticals, Menarini Pharmaceuticals, Napp Pharmaceuticals, TEVA; participation on advisory board at Chiesi, Novartis, GSK, Sandoz; and board leadership at Board of Directors, GINA, outside the submitted work.

Conflict of interest: Kevin Mortimer participated as member of Advisory Boards for AstraZeneca, outside the submitted work.

Conflict of interest: Paulo Pitrez reports consulting fees and lecture honoraria from AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Novartis; travel support from GSK and Boehringer Ingelheim; and held an unpaid position as President of the Brazilian Severe Asthma Group; outside the submitted work.

Conflict of interest: Helen K. Reddel reports grants from AstraZeneca, GlaxoSmithKline, Novartis; consulting fees from Novartis; lecture payments from AstraZeneca, GlaxoSmithKline, Teva, Boehringer Ingelheim, Sanofi, Chiesi; participation on advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Chiesi, Sanofi; acted as Chair of Scientific Committee and Member of Board of Directors for Global Initiative for Asthma, and acted as Member of Australian Asthma Guidelines Committee for National Asthma Council; outside the submitted work.

Conflict of interest: Aziz Sheikh reports grants from HDRUK BREATHE Hub, Asthma UK Centre for Applied Research; and participated in the AstraZeneca Unmet Asthma Need Working Group; outside the submitted work.

Conflict of interest: Arzu A. Yorgancioglu reports grants from MSD, Astra Zeneca, Sanofi, Novartis; consulting fees from AstraZeneca, GSK, Novartis, Sanofi, Chiesi, Deva; lecture honoraria from Astra Zeneca, Abdi İbrahim, GSK, Novartis, Sandoz, Chiesi, Vem İlaç; advisory board participation from GSK, Astra Zeneca; outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received October 15, 2021.
  • Copyright ©The authors 2021.
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

PreviousNext
Back to top
View this article with LENS
Vol 60 Issue 2 Table of Contents
European Respiratory Journal: 60 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes
Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, Christopher E. Brightling, Guy G. Brusselle, Roland Buhl, Alvaro A. Cruz, Liesbeth Duijts, Jeffrey M. Drazen, J. Mark FitzGerald, Louise J. Fleming, Hiromasa Inoue, Fanny W. Ko, Jerry A. Krishnan, Mark L. Levy, Jiangtao Lin, Kevin Mortimer, Paulo M. Pitrez, Aziz Sheikh, Arzu A. Yorgancioglu, Louis-Philippe Boulet
European Respiratory Journal Jan 2021, 2102730; DOI: 10.1183/13993003.02730-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes
Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, Christopher E. Brightling, Guy G. Brusselle, Roland Buhl, Alvaro A. Cruz, Liesbeth Duijts, Jeffrey M. Drazen, J. Mark FitzGerald, Louise J. Fleming, Hiromasa Inoue, Fanny W. Ko, Jerry A. Krishnan, Mark L. Levy, Jiangtao Lin, Kevin Mortimer, Paulo M. Pitrez, Aziz Sheikh, Arzu A. Yorgancioglu, Louis-Philippe Boulet
European Respiratory Journal Jan 2021, 2102730; DOI: 10.1183/13993003.02730-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Task Force report: European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
  • European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases
  • Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis
Show more Task force report

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society